Nadine Beauger
Director/Miembro de la Junta en Immune Biosolutions, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Frédéric Leduc | M | - |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | 12 años |
Guy Sauvageau | M | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Simon Gaudreau | M | - |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | 12 años |
Jean-François Larrivée | M | - |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | 12 años |
David Millette | M | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Louise Proulx | M | 73 |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | 4 años |
Yves Eric Laliberté | M | - |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | - |
Luc Paquet | M | 59 |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | - |
Richard D. Cherney | M | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Michael Hanley | M | 58 |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Nicholas Franco | M | 61 |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | 1 años |
Michael May | M | 56 |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Bruno Maranda | M | - |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | - |
Anne Marinier | F | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Canadá | 14 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Nadine Beauger
- Red Personal